*DISCLAIMER for Dosing Calculator:
By using this resource, you agree to the following: This Dosing Calculator is being provided "AS IS" and is intended for use only by qualified healthcare providers. All calculations should be confirmed before use. Genentech makes no claims as to the accuracy of the information contained herein. The information being provided is not a substitute for clinical judgment. Neither Genentech, nor any other party involved in the preparation or publication of this site, shall be liable to you or others for any decisions made or actions taken by you or others in reliance on this information. ACTEMRA should not be infused concomitantly in the same intravenous line with other drugs. No physical or biochemical compatibility studies have been conducted to evaluate the co-administration of ACTEMRA with other drugs. The infusion should be administered over 60 minutes, and must be administered with an infusion set. Do not administer as an intravenous push or bolus. Dosing Calculator should not replace professional judgment or clinical experience. For additional dosing information, please refer to the Prescribing Information. Dosing Calculator is not a substitute for medical examination.
ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA.
WARNINGS AND PRECAUTIONS
Laboratory Parameters
Neutropenia
Treatment with ACTEMRA was associated with a higher incidence of neutropenia. Infections have been uncommonly reported in association with treatment-related neutropenia in long-term extension studies and postmarketing clinical experience.
Thrombocytopenia
Treatment with ACTEMRA was associated with a reduction in platelet counts. Treatment-related reduction in platelets was not associated with serious bleeding events in clinical trials.
Elevated Liver Enzymes
During randomized controlled studies, treatment with ACTEMRA was associated with a higher incidence of transaminase elevations. Increased frequency and magnitude of these elevations was observed when potentially hepatotoxic drugs (e.g., MTX) were used in combination with ACTEMRA.
Lipid Abnormalities
Treatment with ACTEMRA was associated with increases in lipid parameters such as total cholesterol, triglycerides, LDL cholesterol, and/or HDL cholesterol.
Brunner HI, et al. Ann Rheum Dis. 2015;74:1110-1117.
Brunner HI, et al. Ann Rheum Dis. 2015;74:1110-1117.
Data on file. Genentech, Inc.
Data on file. Genentech, Inc.
Brunner H, Ruperto N, Zuber A, et al. Arthritis & Rheumatism. 2012;64(10S):S682.
Brunner H, Ruperto N, Zuber A, et al. Arthritis & Rheumatism. 2012;64(10S):S682.
Brunner HI, et al. Identification of optimal subcutaneous doses of tocilizumab in children with polyarticular-course juvenile idiopathic arthritis. Presented at the 2017 Pediatric Rheumatology Symposium in Houston, TX; May 17-20, 2017. PRSYM Oral Presentation.
Brunner HI, et al. Identification of optimal subcutaneous doses of tocilizumab in children with polyarticular-course juvenile idiopathic arthritis. Presented at the 2017 Pediatric Rheumatology Symposium in Houston, TX; May 17-20, 2017. PRSYM Oral Presentation.
ACTEMRA [package insert]. South San Francisco, CA: Genentech, Inc.
ACTEMRA [package insert]. South San Francisco, CA: Genentech, Inc.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.